DANTROLENE SODIUM Drug Patent Profile
✉ Email this page to a colleague
When do Dantrolene Sodium patents expire, and what generic alternatives are available?
Dantrolene Sodium is a drug marketed by Elite Labs Inc, Impax Labs, Eugia Pharma Speclts, and Hikma. and is included in four NDAs.
The generic ingredient in DANTROLENE SODIUM is dantrolene sodium. There are five drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the dantrolene sodium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Dantrolene Sodium
A generic version of DANTROLENE SODIUM was approved as dantrolene sodium by IMPAX LABS on March 1st, 2005.
Summary for DANTROLENE SODIUM
US Patents: | 0 |
Applicants: | 4 |
NDAs: | 4 |
Finished Product Suppliers / Packagers: | 9 |
Raw Ingredient (Bulk) Api Vendors: | 133 |
Clinical Trials: | 2 |
Patent Applications: | 830 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for DANTROLENE SODIUM |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for DANTROLENE SODIUM |
What excipients (inactive ingredients) are in DANTROLENE SODIUM? | DANTROLENE SODIUM excipients list |
DailyMed Link: | DANTROLENE SODIUM at DailyMed |
Recent Clinical Trials for DANTROLENE SODIUM
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Beth Israel Deaconess Medical Center | Phase 2 |
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Phase 1/Phase 2 |
Washington University School of Medicine | Phase 1/Phase 2 |
Pharmacology for DANTROLENE SODIUM
Drug Class | Skeletal Muscle Relaxant |
Physiological Effect | Decreased Striated Muscle Contraction Decreased Striated Muscle Tone |